Bortezomib Impurities

Bortezomib injection is used to treat multiple myeloma (blood plasma cell cancer) in individuals with or without a prior history of therapy, as well as mantle cell lymphoma. Bortezomib is an antineoplastic agent (cancer medication).

Show
per page
Impurity structure Parent Drug Name Name of Impurity Catalogue No. CAS No.
Bortezomib (R,S)-Enantiomer Bortezomib

Bortezomib (R,S)-Enantiomer

VE006271 1132709-16-0
Bortezomib (S,S)-Diastereomer Bortezomib

Bortezomib (S,S)-Diastereomer

VE006142 1132709-14-8
Bortezomib Acid Impurity Bortezomib

Bortezomib Acid Impurity

VE006535 114457-94-2
Bortezomib Acid Methyl Ester Bortezomib

Bortezomib Acid Methyl Ester

VE007391 73058-37-4
Bortezomib Acid R-Isomer Bortezomib

Bortezomib Acid R-Isomer

VE007728 1608986-16-8
Bortezomib Acid R-Isomer Methyl Ester Bortezomib

Bortezomib Acid R-Isomer Methyl Ester

VE007392 N/A
Bortezomib Hydroxy Impurity Bortezomib

Bortezomib Hydroxy Impurity

VE006536 N/A
Bortezomib Impurity 10 Bortezomib

Bortezomib Impurity 10

VE007398 390800-88-1
Bortezomib Impurity 11 Bortezomib

Bortezomib Impurity 11

VE007399 862895-00-9
Bortezomib Impurity 12 Bortezomib

Bortezomib Impurity 12

VE0012813 886979-78-8
Bortezomib Impurity 13 Bortezomib

Bortezomib Impurity 13

VE0012814 886979-81-3
Bortezomib Impurity 15 Bortezomib

Bortezomib Impurity 15

VE007400 1259300-03-2
Bortezomib Impurity 16 Bortezomib

Bortezomib Impurity 16

VE0012816 N/A
Bortezomib Impurity 18 Bortezomib

Bortezomib Impurity 18

VE0012834 N/A
Bortezomib Impurity 19 Bortezomib

Bortezomib Impurity 19

VE0012835 N/A
Bortezomib Impurity 2 (Mixture of (1S,2R)-Isomer and (1R,2R)-Isomer) Bortezomib

Bortezomib Impurity 2 (Mixture of (1S,2R)-Isomer and (1R,2R)-Isomer)

VE0012815 N/A
Bortezomib Impurity 2 (RR-Isomer) Bortezomib

Bortezomib Impurity 2 (RR-Isomer)

VE0012837 N/A
Bortezomib Impurity 20 Bortezomib

Bortezomib Impurity 20

VE007401 89618-77-9
Bortezomib Impurity 22 Bortezomib

Bortezomib Impurity 22

VE0012836 N/A
Bortezomib Impurity 26 Bortezomib

Bortezomib Impurity 26

VL1200005 78-77-3
Bortezomib Impurity 27 Bortezomib

Bortezomib Impurity 27

VL1200010 63-91-2
Bortezomib Impurity 28 Bortezomib

Bortezomib Impurity 28

VL1200008 18942-49-9
Bortezomib impurity 29 Bortezomib

Bortezomib impurity 29

VL1200006 89-01-0
Bortezomib Impurity 3 Bortezomib

Bortezomib Impurity 3

VE0014323 N/A
Bortezomib Impurity 30 Bortezomib

Bortezomib Impurity 30

VL1200007 513-36-0
Bortezomib Impurity 31 Bortezomib

Bortezomib Impurity 31

VL1200009 84110-40-7
Bortezomib Impurity 33 TriHCl Bortezomib

Bortezomib Impurity 33 TriHCl

VE0012839 N/A
Bortezomib Impurity 34 Bortezomib

Bortezomib Impurity 34

VE0012841 N/A
Bortezomib Impurity 35 Bortezomib

Bortezomib Impurity 35

VE0012842 N/A
Bortezomib Impurity 37 Trifluoroacetate Bortezomib

Bortezomib Impurity 37 Trifluoroacetate

VE0012843 477254-69-6
Bortezomib Impurity 38 Bortezomib

Bortezomib Impurity 38

VE0012811 N/A
Bortezomib Impurity 39 Bortezomib

Bortezomib Impurity 39

VE0012812 N/A
Bortezomib Impurity 4 Bortezomib

Bortezomib Impurity 4

VE007395 862894-96-0
Bortezomib Impurity 42 (Mixture of Diastereomers) Bortezomib

Bortezomib Impurity 42 (Mixture of Diastereomers)

VE0012844 N/A
Bortezomib Impurity 44 Bortezomib

Bortezomib Impurity 44

VE0012845 N/A
Bortezomib Impurity 49 Bortezomib

Bortezomib Impurity 49

VE0012872 N/A
Bortezomib Impurity 5 Bortezomib

Bortezomib Impurity 5

VE007396 2379402-85-2
Bortezomib Impurity 50 Bortezomib

Bortezomib Impurity 50

VE0012873 84110-34-9
Bortezomib Impurity 54 HCl Bortezomib

Bortezomib Impurity 54 HCl

VE0012876 205393-21-1
Bortezomib Impurity 59 Bortezomib

Bortezomib Impurity 59

VE0019957 590-86-3
Bortezomib Impurity 60 Bortezomib

Bortezomib Impurity 60

VE0012880 2210228-73-0
Bortezomib Impurity 66 Bortezomib

Bortezomib Impurity 66

VE0012881 N/A
Bortezomib Impurity 75 Bortezomib

Bortezomib Impurity 75

VE0012882 85167-14-2
Bortezomib Impurity 84 Bortezomib

Bortezomib Impurity 84

VE0012809
Bortezomib Impurity 85 Bortezomib

Bortezomib Impurity 85

VE0012810 N/A
Bortezomib Impurity 9 Bortezomib

Bortezomib Impurity 9

VE007397 1194235-41-0
Bortezomib Impurity A (Na Salt) Bortezomib

Bortezomib Impurity A (Na Salt)

VE0012505 1093959-75-1
Bortezomib Impurity B Bortezomib

Bortezomib Impurity B

VL1200011 N/A
Bortezomib Impurity C Bortezomib

Bortezomib Impurity C

VE0014322 N/A
Bortezomib Impurity D Bortezomib

Bortezomib Impurity D

VE0012506 289472-81-7

Bortezomib Related Compound

It inhibits the development of cancer cells, which are finally killed by the body.

References

FAQ

What is the therapeutic category of bortezomib?

Proteasome inhibitor and anti-cancer drug bortezomib is used to treat refractory multiple myeloma and some lymphomas.

What is the action of bortezomib?

For cells to maintain homeostasis, the proteasomal system is crucial to cellular protein turnover. The 26S proteasome’s chymotrypsin-like component is inhibited by the drug bortezomib, which also prevents the degradation of a number of pro-apoptotic proteins.

What is bortezomib cancer treatment?

By inhibiting some of the enzymes required for cell development, the drug bortezomib may prevent the formation of cancerous cells. Lenalidomide is an example of a chemotherapy treatment that stops the growth of cancer cells in one of three ways: by killing the cells, by preventing their division, or by preventing their dissemination.